NCT01980277终止1 期
A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008
Institut Paoli-Calmettes4 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2014年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 68
- 试验地点
- 4
- 主要终点
- Phase II: objective response rate (ORR)
研究概览
简要总结
The overall rationale of this study evaluating tolerance and efficacy of LY2780301 in combination with paclitaxel in HER2-negative, inoperable locally advanced or metastatic breast cancer (MBC) is based on :
- the medical need in this population with either hormonal-resistant or unsensitive and/or rapidly progressive disease
- the preclinical evidences for involvement of PI3K/AKT pathway in tumor progression and drug resistance, including taxanes as well as its potential reversion by AKT inhibition
- the high level of frequency of PI3K/AKT activation in HER2-negative MBC
- the in vitro and in vivo preclinical activity of LY2780301, and its synergistic combination with various anticancer agents, including taxanes
- the favourable profile of tolerance of LY2780301 in phase I trial
Weekly paclitaxel is conventionally administered at 80 mg/m²/week and is a standard treatment in breast cancer (BC) As described above, LY2780301 500 mg once daily has been established as the RP2D in phase I single agent trial.
Evidence of pharmacodynamic activity was noted at 400-500 mg QD. Conservatively, the first dose level to be explored will be LY2780301 400 mg QD and paclitaxel 70 mg/m²/week.
详细描述
RATIONALE OF THE STUDY DESIGN
The purpose of this study will be:
- to determine the recommended phase 2 dose (RP2D) for LY2780301 in combination with weekly paclitaxel in HER2-negative, inoperable locally advanced or MBC patients
- to estimate the objective response rate (ORR) of the combination in first-line treated, HER2-negative, inoperable locally advanced or MBC patients. In addition, this study will assess the role of PI3K/AKT/S6 pathway activation as potential predictive factor for response to LY2780301 in this patient population.
This trial will be a phase Ib/II prospective, multicentre, open label, uncontrolled study.
Phase Ib will use a continuous reassessment method (CRM) design, allowing to reach safely and quickly the MTD and the RP2D of the combination, but ensuring the treatment of at least 18 patients to secure the tolerance profile.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male patients (≥ 18 years)
- •WHO/ECOG performance status ≤ 1 for phase Ib part, < 2 for phase II part
- •Patient with histologically confirmed inoperable locally advanced BC or MBC
- •Patient with tumor biopsy from metastatic tissue containing more than 50% tumor cells
- •Patient has known hormone receptor (ER/PR) status, positive and/or negative (local laboratory testing)
- •Patient has HER2-negative disease: IHC 0, 1 + or 2+ and/or in situ hybridization (FISH, CISH, SISH) negative (local laboratory testing)
- •Phase Ib: Patient has measurable or non-measurable disease according to RECIST 1.1 criteria only Phase II: Patient has measurable disease according to RECIST 1.1 criteria only
- •Patient has adequate bone marrow and organ function
- •Patient is able to swallow and retain oral medication
- •Negative serum pregnancy test within ≤ one week before first dose for childbearing potential women and for women < 12 months after the onset of menopause
- •Males and Females of childbearing potential (FCBP) must agree to use a reliable form of contraception or to practice complete abstinence from heterosexual intercourse during the study treatment (and 3 months after the end of treatment)
- •Life expectancy > 3 months
- •Affiliation to social security or beneficiary
- •Patient has signed the Informed Consent (ICF) prior to any screening procedures being performed
排除标准
- •Previous treatment with AKT or PI3K inhibitor
- •no previous cytotoxic treatment for metastatic or inoperable locally advanced disease (phase II part); Adjuvant/neoadjuvant therapy will be counted as prior line of therapy for metastatic/recurrent disease if the patient had a progression/recurrence within 6 months after completion of the therapy (12 months for taxane-based therapy). Previous hormonal treatment for metastatic or locally advanced disease is allowed.
- •Patient with bone metastases only
- •Patient has symptomatic CNS metastases; patients with asymptomatic CNS metastases may participate in this trial. The patient must have completed any prior local treatment for CNS metastases ≥ 15 days prior to the start of study treatment (including radiotherapy and/or surgery) and must have completed corticosteroid therapy.
- •Patient has a concurrent malignancy or malignancy within 3 years of study enrollment
- •Patient has received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study
- •Patients who have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C; 3 weeks for weekly chemotherapy) prior to starting study drug or who have not recovered from side effects of such therapy
- •Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half-lives prior to starting study drug or who have not recovered from side effects of such therapy
- •Patients who have undergone major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy
- •Known diagnosis of human immunodeficiency virus (HIV) infection
- •Patient has a known hypersensitivity to paclitaxel or other products containing Cremophor
- •Patient has a contraindication to use the paclitaxel standard pre-treatment such as corticosteroids
- •Patients with any peripheral neuropathy ≥ CTCAE grade 2
- •Patients with diarrhea ≥ CTCAE grade 2
- •Patient has active cardiac disease
- •Patient has a history of cardiac dysfunction including
- •Patients who are currently receiving treatment with medication with a known risk prolong the QT interval or inducing Torsades de Pointes
- •Patient has poorly controlled diabetes mellitus (HbA1c > 8 %)
- •Other concurrent severe and/or uncontrolled concomitant medical conditions
- •Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LY2780301
- •Patient is currently receiving treatment with drugs known to be substrate of isoenzyme CYP3A4
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)
- •Patient who does not apply effective contraception during the study and through the duration as defined below after the final dose of study treatment.
- •Other experimental treatment
研究组 & 干预措施
LY2780301 + paclitaxel
Experimental
The following dose-levels will be investigated:
- Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week
- Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week
- Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week
A dose reduction could be explored:
- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week
干预措施: LY2780301 + paclitaxel (Drug)
结局指标
主要结局
Phase II: objective response rate (ORR)
时间窗: until progression assessed up to 18 months
To estimate the efficacy of daily LY2780301 when administered orally at the RP2D in combination with weekly intravenous (IV) paclitaxel in HER2-negative, inoperable locally advanced or MBC patients, in the overall population and in patients with activation of PI3/AKT/S6 pathway
Phase Ib: recommended phase II dose (RP2D)
时间窗: Day 28
To determine the recommended phase II dose (RP2D) of daily LY2780301 when administered orally in combination with weekly intravenous (IV) paclitaxel in HER2-negative, inoperable locally advanced or MBC patients
次要结局
- safety(up to the end of treatment or maximum 6 months)
- clinical benefit (CB)(until progression assessed up to 18 months)
- progression-free survival (PFS)(until progression assessed up to 18 months)
- pharmacokinetics(D1, D8, D15, D22, D28 post dose)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)Hepatocellular CarcinomaNCT02240433Eli Lilly and Company9
已完成
1 期
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the BodyPancreatic NeoplasmsNCT02154646Eli Lilly and Company6
终止
3 期
A Study in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT01202773Eli Lilly and Company456
终止
3 期
A Rheumatoid Arthritis Study in Participants on a Background Treatment of MethotrexateRheumatoid ArthritisNCT01198002Eli Lilly and Company1,041
已完成
3 期
A Rheumatoid Arthritis Study in ParticipantsRheumatoid ArthritisNCT01202760Eli Lilly and Company1,004